Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective

References

• Jean-François D, Theophanous A. Cyprus and the EU: Appraisal and Challenges. Policy Paper No. 58, Notre Europe, September 2012
   Google Scholar
• OECD. Health at a Glance: Europe 2012. OECD Publishing; doi: 10.1787/9789264183896-en
   Google Scholar
• OECD/European Union, Medical technologies: CT scanners and MRI units. In: Health at a Glance: Europe 2010. OECD Publishing
   Google Scholar
• Forman H. MRI and CT imaging: how fast can reimbursement be cut? AJR Am J Roentgenol 2006;187(3):602-
   Google Scholar
• Kanavos P, Schurer W, Vogler S. EMINET. The pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices. 2011
   Google Scholar
• Petrou P. Power of r :pharmaceutical sales decomposition in Cyprus Public Health Care Sector and determinants of drug expenditure evolution. Any Lessons learned? Expert Rev Pharmacoecon Outcomes Res 2014;14(2):289-300
   PubMed Web of Science ®Google Scholar
• Buysse M, Laing RO, Mantel K. Impact of the economic recession on the pharmaceutical sector. WHO collaborating centre for pharmacoepidemiology & pharmaceutical Policy Analysis 2010
   Google Scholar
• Memorandum of understanding on specific economic policy conditionality. Republic of Cyprus, Nicosia. 2013
   Google Scholar
• Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. Lancet 2003;362:111-17
   PubMed Web of Science ®Google Scholar
• Badiaa J, et al. Spanish health care cuts: penny wise and pound foolish? Health Policy 2012;106:23-8
   PubMedGoogle Scholar
• Castellana A. Impact of the economic crisis on the Italian public healthcare expenditure. Available from: http://arxiv.org/abs/1205.2863
   Google Scholar
• Kentikelenis A, Karanikolos M, Papanicolas I, et al. Health effects of financial crisis: omens of a Greek tragedy. Lancet 2011;378:1457-8
   PubMed Web of Science ®Google Scholar
• Kronenberg C, Barros P. Catastrophic health expenditure drivers and protection:the portuguese case Health Policy. 2014;115(1):44-51
   Google Scholar
• Vandoros S, Stargardt T. Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy 2013;109:1-6
   PubMed Web of Science ®Google Scholar
• Economou M, Madianos M, Theleritis C, et al. Increased suicidality aimd economic crisis in Greece. Lancet 2011;378:1459
   PubMed Web of Science ®Google Scholar
• Vandoros S, Hessel P, Leone T, Avendano M. Have health trends worsened in Greece as a result of the financial crisis? a quasi-experimental approach. Eur J Public Health 2013;23(5):727-31
   PubMed Web of Science ®Google Scholar
• Catalano R. Health, Medical Care, and Economic Crisis. N Engl J Med 2009;360(8):749-75
   PubMed Web of Science ®Google Scholar
• Mendoza RU. Crises and inequality: lessons from the global food, fuel, financial and economic crises of 2008–10. Global Policy 2011;2(3):259-71
   Google Scholar
• Weintraub W, Cohen D. The limits of cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 2009;2:55-8
   PubMed Web of Science ®Google Scholar
• Gridchyna L, Aulois-Griot M, Maurain C, Bégaud B. How innovative are pharmaceutical innovations? The case of medicines financed through add-on payments outside of the French DRG-based hospital payment system. Health Policy 2012;104:69-75
   PubMed Web of Science ®Google Scholar
• Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998;80(1):108 -18
   Web of Science ®Google Scholar
• Lambrelli D, O’Donnell O. The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece. Health Policy 2011;101:162-71
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Appraising end of life medicines 2008. Available from: www.nice.org.uk/media/26E/43/Endoflifemedicines.pdf [Last accessed December 2013]
   Google Scholar
• Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines in generalized cost effectiveness analysis. Health Econ 2000;9:235-51
   PubMed Web of Science ®Google Scholar
• Belvis A, Ferrè F, Specchia ML, et al. The financial crisis in Italy: implications for the healthcare sector. Health Policy 2012;106:10-16
   PubMedGoogle Scholar
• Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care 1990;28:907-17
   PubMedGoogle Scholar
• Gibson TB, Mclaughlin CG, Smith DG. A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry 2005;42:293-310
   PubMedGoogle Scholar
• General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Available at www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf
   Google Scholar
• McGuire A, Raikou M, Kanavos P. Pricing pharmaceuticals: Value based pricing in what sense? Eurohealth 2008;14(2):3-6
   Google Scholar
• Persson U. Value based pricing in Sweden: lessons for design? Swedish Institute for Health Economics seminar briefing. 2012; no12
   Google Scholar
• Value for money pharmaceuticals: fostering constructive collaboration among stakeholdes. Eureopaen Innovation Leadership Network 2007
   Google Scholar
• Goeree R, He J, O’Reilly D, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res 2011;3:89-104
   PubMedGoogle Scholar
• Menabde N. The financial crisis and global health Report of a High-Level Consultation. Investing in health systems in times of economic crisis. Is there a role for markets? World Health Organization WHO Regional Office for Europe
   Google Scholar